Therapeutic Approaches to Increase the Survival Rate of Cancer Patients in the Younger and Older Population


Cite item

Full Text

Abstract

Various developments have been observed in the treatment of cancer patients, such as higher survival rates and better treatment outcomes. However, expecting similar outcomes in older patients remains a challenge. The main reason for this conclusion is the exclusion of older people from clinical trials for cancer drugs, as well as other factors, such as comorbidity, side effects, age-related frailties and their willingness to undergo multiple treatments. However, the discovery of new techniques and drug combinations has led to a significant improvement in the survival of the elderly population after the onset of the disease. On the other hand, cancer treatments have not become more complex for the younger population when compared to the older population, as the younger population tends to respond well to treatment trials and their physiological conditions are stable in response to treatments. In summary, this review correlates recent cancer treatment strategies and the corresponding responses and survival outcomes of older and younger patients.

About the authors

Tharrun Paul

Cancer Science Laboratory, Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology

Email: info@benthamscience.net

Kanagaraj Palaniyandi

Cancer Science Laboratory, Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology

Author for correspondence.
Email: info@benthamscience.net

Dhanavathy Gnanasampanthapandian

Cancer Science Laboratory, Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology

Author for correspondence.
Email: info@benthamscience.net

References

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72(1): 7-33. doi: 10.3322/caac.21708 PMID: 35020204
  2. Van Herck Y, Feyaerts A, Alibhai S, et al. Is cancer biology different in older patients? Lancet Healthy Longev 2021; 2(10): e663-77. doi: 10.1016/S2666-7568(21)00179-3 PMID: 36098020
  3. Age and Cancer Risk 2021. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/age
  4. Laconi E, Marongiu F, DeGregori J. Cancer as a disease of old age: Changing mutational and microenvironmental landscapes. Br J Cancer 2020; 122(7): 943-52. doi: 10.1038/s41416-019-0721-1 PMID: 32042067
  5. Chatsirisupachai K, Lagger C, de Magalhães JP. Age-associated differences in the cancer molecular landscape. Trends Cancer 2022; 8(11): 962-71. doi: 10.1016/j.trecan.2022.06.007 PMID: 35811230
  6. Berben L, Floris G, Wildiers H, Hatse S. Cancer and aging: Two tightly interconnected biological processes. Cancers 2021; 13(6): 1400. doi: 10.3390/cancers13061400 PMID: 33808654
  7. Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science 2017; 355(6331): 1330-4. doi: 10.1126/science.aaf9011 PMID: 28336671
  8. van den Beld AW, Kaufman JM, Zillikens MC, Lamberts SWJ, Egan JM, van der Lely AJ. The physiology of endocrine systems with ageing. Lancet Diabetes Endocrinol 2018; 6(8): 647-58. doi: 10.1016/S2213-8587(18)30026-3 PMID: 30017799
  9. Pataky MW, Young WF, Nair KS. Hormonal and metabolic changes of aging and the influence of lifestyle modifications. Mayo Clin Proc 2021; 96(3): 788-814. doi: 10.1016/j.mayocp.2020.07.033 PMID: 33673927
  10. Ma H, Bernstein L, Ross RK, Ursin G. Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: Results from a case–control and a case–case comparison. Breast Cancer Res 2006; 8(4): R39. doi: 10.1186/bcr1514 PMID: 16846528
  11. Akoko LO, Rutashobya AK, Lutainulwa EW, Mwanga AH, Kivuyo SL. The effect of reproductive, hormonal, nutritional and lifestyle on breast cancer risk among black Tanzanian women: A case control study. PLoS One 2022; 17(2): e0263374. doi: 10.1371/journal.pone.0263374 PMID: 35139096
  12. Warraich UA, Hussain F, Kayani HUR. Aging - Oxidative stress, antioxidants and computational modeling. Heliyon 2020; 6(5): e04107. doi: 10.1016/j.heliyon.2020.e04107 PMID: 32509998
  13. Rajendran P, Jayaraman S, Munuswamy-Ramanujam G, et al. Cancer stem cells: Reactive oxygen species-induced drug resistance in cancer. In: Chakraborti S, Ed. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects.Singapore: Springer Nature Singapore 2021; pp. 1-23.
  14. Waris G, Ahsan H. Reactive oxygen species: Role in the development of cancer and various chronic conditions. J Carcinog 2006; 5(1): 14. doi: 10.1186/1477-3163-5-14 PMID: 16689993
  15. Nimse SB, Sonawane MD, Song KS, Kim T. Biomarker detection technologies and future directions. Analyst 2016; 141(3): 740-55. doi: 10.1039/C5AN01790D PMID: 26583164
  16. Garcia-Schwarz G, Santiago JG. Rapid high-specificity microRNA detection using a two-stage isotachophoresis assay. Angew Chem Int Ed 2013; 52(44): 11534-7. doi: 10.1002/anie.201305875 PMID: 24038732
  17. Lee H, Park JE, Nam JM. Bio-barcode gel assay for microRNA. Nat Commun 2014; 5(1): 3367. doi: 10.1038/ncomms4367 PMID: 24569571
  18. Law WC, Yong KT, Baev A, Prasad PN. Sensitivity improved surface plasmon resonance biosensor for cancer biomarker detection based on plasmonic enhancement. ACS Nano 2011; 5(6): 4858-64. doi: 10.1021/nn2009485 PMID: 21510685
  19. Krishnan S, Mani V, Wasalathanthri D, Kumar CV, Rusling JF. Attomolar detection of a cancer biomarker protein in serum by surface plasmon resonance using superparamagnetic particle labels. Angew Chem Int Ed 2011; 50(5): 1175-8. doi: 10.1002/anie.201005607 PMID: 21268221
  20. Syriopoulou E, Bower H, Andersson TML, Lambert PC, Rutherford MJ. Estimating the impact of a cancer diagnosis on life expectancy by socio-economic group for a range of cancer types in England. Br J Cancer 2017; 117(9): 1419-26. doi: 10.1038/bjc.2017.300 PMID: 28898233
  21. Yeh JM, Ward ZJ, Chaudhry A, et al. Life expectancy of adult survivors of childhood cancer over 3 decades. JAMA Oncol 2020; 6(3): 350-7. doi: 10.1001/jamaoncol.2019.5582 PMID: 31895405
  22. Botta L, Dal Maso L, Guzzinati S, et al. Changes in life expectancy for cancer patients over time since diagnosis. J Adv Res 2019; 20: 153-9. doi: 10.1016/j.jare.2019.07.002 PMID: 31467707
  23. Miglietta F, Bottosso M, Griguolo G, Dieci MV, Guarneri V. Major advancements in metastatic breast cancer treatment: When expanding options means prolonging survival. ESMO Open 2022; 7(2): 100409. doi: 10.1016/j.esmoop.2022.100409 PMID: 35227965
  24. Hoppenz P, Els-Heindl S, Beck-Sickinger AG. Peptide-drug conjugates and their targets in advanced cancer therapies. Front Chem 2020; 8: 571. doi: 10.3389/fchem.2020.00571 PMID: 32733853
  25. Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 2022; 72(5): 409-36. doi: 10.3322/caac.21731 PMID: 35736631
  26. Bae K, Kim E, Kong JS, et al. Integrative cancer treatment may have a survival benefit in patients with lung cancer. Medicine 2019; 98(26): e16048. doi: 10.1097/MD.0000000000016048 PMID: 31261510
  27. Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60(7): 1878-86. PMID: 10766175
  28. de Steur WO, van Amelsfoort RM, Hartgrink HH, et al. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. Ann Oncol 2021; 32(3): 360-7. doi: 10.1016/j.annonc.2020.11.004 PMID: 33227408
  29. Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the dutch randomized PREOPANC trial. J Clin Oncol 2022; 40(11): 1220-30. doi: 10.1200/JCO.21.02233 PMID: 35084987
  30. Pulumati A, Pulumati A, Dwarakanath BS, Verma A, Papineni RVL. Technological advancements in cancer diagnostics: Improvements and limitations. Cancer Rep 2023; 6(2): e1764. doi: 10.1002/cnr2.1764 PMID: 36607830
  31. Ileana Dumbrava E, Meric-Bernstam F, Yap TA. Challenges with biomarkers in cancer drug discovery and development. Expert Opin Drug Discov 2018; 13(8): 685-90. doi: 10.1080/17460441.2018.1479740 PMID: 29792354
  32. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ 2007; 176(13): 1853-8. doi: 10.1503/cmaj.060955 PMID: 17576986
  33. Mehrgou A, Akouchekian M. The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. Med J Islam Repub Iran 2016; 30: 369. PMID: 27493913
  34. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol 2012; 6(2): 140-6. doi: 10.1016/j.molonc.2012.01.010 PMID: 22356776
  35. Wu L, Qu X. Cancer biomarker detection: Recent achievements and challenges. Chem Soc Rev 2015; 44(10): 2963-97. doi: 10.1039/C4CS00370E PMID: 25739971
  36. Lesterhuis WJ, Bosco A, Millward MJ, Small M, Nowak AK, Lake RA. Dynamic versus static biomarkers in cancer immune checkpoint blockade: Unravelling complexity. Nat Rev Drug Discov 2017; 16(4): 264-72. doi: 10.1038/nrd.2016.233 PMID: 28057932
  37. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014; 20(5): 548-54. doi: 10.1038/nm.3519 PMID: 24705333
  38. Han X, Wang J, Sun Y. Circulating tumor DNA as biomarkers for cancer detection. GPB 2017; 15(2): 59-72. doi: 10.1016/j.gpb.2016.12.004 PMID: 28392479
  39. Fakhry C, Waterboer T, Westra WH, et al. Distinct biomarker and behavioral profiles of human papillomavirus-related oropharynx cancer patients by age. Oral Oncol 2020; 101: 104522. doi: 10.1016/j.oraloncology.2019.104522 PMID: 31881446
  40. Yao H, Li C, Tan X. An age stratified analysis of the biomarkers in patients with colorectal cancer. Sci Rep 2021; 11(1): 22464. doi: 10.1038/s41598-021-01850-x PMID: 34789836
  41. Aguiar PN Jr, De Mello RA, Hall P, Tadokoro H, Lima Lopes G. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy 2017; 9(6): 499-506. doi: 10.2217/imt-2016-0150 PMID: 28472902
  42. Nadaraja S, Schledermann D, Herrstedt J, Østrup O, Ditzel HJ. ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy. Acta Oncol 2020; 59(1): 40-7. doi: 10.1080/0284186X.2019.1657941 PMID: 31478407
  43. Szász AM, Lánczky A, Nagy Á, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget 2016; 7(31): 49322-33. doi: 10.18632/oncotarget.10337 PMID: 27384994
  44. Lin P, Xing W, Ren Q, Wang Q, Yan J, Mao G. LncRNAs as theragnostic biomarkers for predicting radioresistance in cancer: A systematic review and meta-analysis. Front Oncol 2022; 12: 767750. doi: 10.3389/fonc.2022.767750 PMID: 35692742
  45. Xie Y, Han J, Xie K, Gou Q. LncRNAs as biomarkers for predicting radioresistance and survival in cancer: A meta-analysis. Sci Rep 2022; 12(1): 18494. doi: 10.1038/s41598-022-21785-1 PMID: 36323697
  46. Rossiello F, Jurk D, Passos JF, d’Adda di Fagagna F. Telomere dysfunction in ageing and age-related diseases. Nat Cell Biol 2022; 24(2): 135-47. doi: 10.1038/s41556-022-00842-x PMID: 35165420
  47. Schumacher B, Pothof J, Vijg J, Hoeijmakers JHJ. The central role of DNA damage in the ageing process. Nature 2021; 592(7856): 695-703. doi: 10.1038/s41586-021-03307-7 PMID: 33911272
  48. Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol 2018; 19(6): e305-16. doi: 10.1016/S1470-2045(18)30348-6 PMID: 29893262
  49. Song C, Cui Z, Hui M, Liu Y, Li Y, Li X. Comparative transcriptomic analysis provides insights into the molecular basis of brachyurization and adaptation to benthic lifestyle in Eriocheir sinensis. Gene 2015; 558(1): 88-98. doi: 10.1016/j.gene.2014.12.048 PMID: 25542812
  50. Massa E, Madeddu C, Astara G, et al. An attempt to correlate a "Multidimensional Geriatric Assessment" (MGA), treatment assignment and clinical outcome in elderly cancer patients: Results of a phase II open study. Crit Rev Oncol Hematol 2008; 66(1): 75-83. doi: 10.1016/j.critrevonc.2007.11.002 PMID: 18164209
  51. Marosi C, Köller M. Challenge of cancer in the elderly. ESMO Open 2016; 1(3): e000020. doi: 10.1136/esmoopen-2015-000020 PMID: 27843603
  52. Fishman WH. Clinical and biological significance of an isozyme tumor marker—PLAP. Clin Biochem 1987; 20(6): 387-92. doi: 10.1016/0009-9120(87)90003-8 PMID: 3325192
  53. Zhang C, Zhang QZ, Zhang K, et al. Dual-biomarker-triggered fluorescence probes for differentiating cancer cells and revealing synergistic antioxidant effects under oxidative stress. Chem Sci 2019; 10(7): 1945-52. doi: 10.1039/C8SC03781G PMID: 30931093
  54. Chinen AB, Guan CM, Ferrer JR, Barnaby SN, Merkel TJ, Mirkin CA. Nanoparticle probes for the detection of cancer biomarkers, cells, and tissues by fluorescence. Chem Rev 2015; 115(19): 10530-74. doi: 10.1021/acs.chemrev.5b00321 PMID: 26313138
  55. Zhang H, Fan J, Wang J, et al. Fluorescence discrimination of cancer from inflammation by molecular response to COX-2 enzymes. J Am Chem Soc 2013; 135(46): 17469-75. doi: 10.1021/ja4085308 PMID: 24200121
  56. Blackburn EH. Structure and function of telomeres. Nature 1991; 350(6319): 569-73. doi: 10.1038/350569a0 PMID: 1708110
  57. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266(5193): 2011-5. doi: 10.1126/science.7605428 PMID: 7605428
  58. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33(5): 787-91. doi: 10.1016/S0959-8049(97)00062-2 PMID: 9282118
  59. Hirano Y, Fujita K, Suzuki K, Ushiyama T, Ohtawara Y, Tsuda F. Telomerase activity as an indicator of potentially malignant adrenal tumors. Cancer 1998; 83(4): 772-6. doi: 10.1002/(SICI)1097-0142(19980815)83:43.0.CO;2-O PMID: 9708944
  60. Yoshida K, Sakamoto S, Sumi S, Higashi Y, Kitahara S. Telomerase activity in renal cell carcinoma. Cancer 1998; 83(4): 760-6. doi: 10.1002/(SICI)1097-0142(19980815)83:43.0.CO;2-Q PMID: 9708942
  61. Anker P, Mulcahy H, Qi Chen X, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999; 18(1): 65-73. doi: 10.1023/A:1006260319913 PMID: 10505546
  62. Sozzi G, Conte D, Leon M, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003; 21(21): 3902-8. doi: 10.1200/JCO.2003.02.006 PMID: 14507943
  63. Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001; 61(12): 4675-8. PMID: 11406535
  64. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14(9): 985-90. doi: 10.1038/nm.1789 PMID: 18670422
  65. Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget 2016; 7(30): 48832-41. doi: 10.18632/oncotarget.9453 PMID: 27223063
  66. Kato R, Hayashi H, Sakai K, et al. CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib. Int J Clin Oncol 2021; 26(9): 1628-39. doi: 10.1007/s10147-021-01947-3 PMID: 34117553
  67. Shah AT, Azad TD, Breese MR, et al. A comprehensive circulating tumor DNA assay for detection of translocation and copy-number changes in pediatric sarcomas. Mol Cancer Ther 2021; 20(10): 2016-25. doi: 10.1158/1535-7163.MCT-20-0987 PMID: 34353895
  68. Siddiqui N, Borden KLB. mRNA export and cancer. Wiley Interdiscip Rev RNA 2012; 3(1): 13-25. doi: 10.1002/wrna.101 PMID: 21796793
  69. Pandolfi PP. Aberrant mRNA translation in cancer pathogenesis: an old concept revisited comes finally of age. Oncogene 2004; 23(18): 3134-7. doi: 10.1038/sj.onc.1207618 PMID: 15094762
  70. Perrotti D, Neviani P. From mRNA metabolism to cancer therapy: Chronic myelogenous leukemia shows the way. Clin Cancer Res 2007; 13(6): 1638-42. doi: 10.1158/1078-0432.CCR-06-2320 PMID: 17363515
  71. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci 2001; 98(24): 13790-5. doi: 10.1073/pnas.191502998 PMID: 11707567
  72. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008; 17(10): 2536-45. doi: 10.1158/1055-9965.EPI-08-0306 PMID: 18842994
  73. Li Y, Elashoff D, Oh M, et al. Serum circulating human mRNA profiling and its utility for oral cancer detection. J Clin Oncol 2006; 24(11): 1754-60. doi: 10.1200/JCO.2005.03.7598 PMID: 16505414
  74. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435(7043): 834-8. doi: 10.1038/nature03702 PMID: 15944708
  75. Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J Pathol 2011; 223(2): 102-15. doi: 10.1002/path.2806 PMID: 21125669
  76. Brase JC, Johannes M, Schlomm T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011; 128(3): 608-16. doi: 10.1002/ijc.25376 PMID: 20473869
  77. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci 2011; 108(9): 3713-8. doi: 10.1073/pnas.1100048108 PMID: 21300873
  78. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 2010; 5(10): e13735. doi: 10.1371/journal.pone.0013735 PMID: 21060830
  79. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64(11): 3753-6. doi: 10.1158/0008-5472.CAN-04-0637 PMID: 15172979
  80. Garcia-Schwarz G, Rogacs A, Bahga SS, Santiago JG. On-chip isotachophoresis for separation of ions and purification of nucleic acids. J Vis Exp 2012; (61): e3890. doi: 10.3791/3890 PMID: 22415002
  81. Wegman DW, Krylov SN. Direct quantitative analysis of multiple miRNAs (DQAMmiR). Angew Chem Int Ed 2011; 50(44): 10335-9. doi: 10.1002/anie.201104693 PMID: 21919168
  82. Gu LQ, Wanunu M, Wang MX, McReynolds L, Wang Y. Detection of miRNAs with a nanopore single-molecule counter. Expert Rev Mol Diagn 2012; 12(6): 573-84. doi: 10.1586/erm.12.58 PMID: 22845478
  83. Wanunu M, Dadosh T, Ray V. Jin J. McReynolds L. Drndić M. Rapid electronic detection of probe-specific microRNAs using thin nanopore sensors. Nat Nanotechnol 2010; 5(11): 807-14. doi: 10.1038/nnano.2010.202 PMID: 20972437
  84. Wang Y, Zheng D, Tan Q, Wang MX, Gu LQ. Nanopore-based detection of circulating microRNAs in lung cancer patients. Nat Nanotechnol 2011; 6(10): 668-74. doi: 10.1038/nnano.2011.147 PMID: 21892163
  85. Paganin-Gioanni A, Bellard E, Paquereau L, Ecochard V, Golzio M, Teissié J. Fluorescence imaging agents in cancerology. Radiol Oncol 2010; 44(3): 142-8. doi: 10.2478/v10019-010-0031-y PMID: 22933906
  86. Dong H, Ding L, Yan F, Ji H, Ju H. The use of polyethylenimine-grafted graphene nanoribbon for cellular delivery of locked nucleic acid modified molecular beacon for recognition of microRNA. Biomaterials 2011; 32(15): 3875-82. doi: 10.1016/j.biomaterials.2011.02.001 PMID: 21354613
  87. Li N, Chang C, Pan W, Tang B. A multicolor nanoprobe for detection and imaging of tumor-related mRNAs in living cells. Angew Chem Int Ed 2012; 51(30): 7426-30. doi: 10.1002/anie.201203767 PMID: 22806948
  88. Si P, Razmi N, Nur O, et al. Gold nanomaterials for optical biosensing and bioimaging. Nanoscale Adv 2021; 3(10): 2679-98. doi: 10.1039/D0NA00961J PMID: 36134176
  89. Lone SN, Nisar S, Masoodi T, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer 2022; 21(1): 79. doi: 10.1186/s12943-022-01543-7 PMID: 35303879
  90. Alix-Panabières C, Pantel K. Liquid biopsy: From discovery to clinical application. Cancer Discov 2021; 11(4): 858-73. doi: 10.1158/2159-8290.CD-20-1311 PMID: 33811121
  91. Macklin A, Khan S, Kislinger T. Recent advances in mass spectrometry based clinical proteomics: Applications to cancer research. Clin Proteomics 2020; 17(1): 17. doi: 10.1186/s12014-020-09283-w PMID: 32489335
  92. Benjamin DJ. The efficacy of surgical treatment of cancer – 20years later. Med Hypotheses 2014; 82(4): 412-20. doi: 10.1016/j.mehy.2014.01.004 PMID: 24480434
  93. Simon C, Nicolai P, Paderno A, Dietz A. Best practice in surgical treatment of malignant head and neck tumors. Front Oncol 2020; 10: 140. doi: 10.3389/fonc.2020.00140 PMID: 32117778
  94. Meulemans J, Hauben E, Peeperkorn S, Nuyts S, Delaere P, Vander Poorten V. Transoral Laser Microsurgery (TLM) for glottic cancer: Prospective assessment of a new pathology workup protocol. Front Surg 2020; 7: 56. doi: 10.3389/fsurg.2020.00056 PMID: 33005622
  95. Wyld L, Audisio RA, Poston GJ. The evolution of cancer surgery and future perspectives. Nat Rev Clin Oncol 2015; 12(2): 115-24. doi: 10.1038/nrclinonc.2014.191 PMID: 25384943
  96. Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: Clinical advances and challenges. Nat Rev Drug Discov 2020; 19(9): 589-608. doi: 10.1038/s41573-020-0073-9 PMID: 32728208
  97. Vijayakumar K, Anand K, Boomi P, Surendrakumar R. Theranostics and radiopharmaceuticals in cancer treatment.Handbook on Nanobiomaterials for Therapeutics and Diagnostic Applications. Elsevier 2021; pp. 341-60. doi: 10.1016/B978-0-12-821013-0.00020-9
  98. Baumann M, Krause M, Overgaard J, et al. Radiation oncology in the era of precision medicine. Nat Rev Cancer 2016; 16(4): 234-49. doi: 10.1038/nrc.2016.18 PMID: 27009394
  99. Hall WA, Bergom C, Thompson RF, et al. Precision oncology and genomically guided radiation therapy: A report from the american society for radiation oncology/american association of physicists in medicine/national cancer institute precision medicine conference. Int J Radiat Oncol Biol Phys 2018; 101(2): 274-84. doi: 10.1016/j.ijrobp.2017.05.044 PMID: 28964588
  100. Bristow RG, Alexander B, Baumann M, et al. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: A guideline by the American Society for Radiation Oncology. Lancet Oncol 2018; 19(5): e240-51. doi: 10.1016/S1470-2045(18)30096-2 PMID: 29726389
  101. Kręcisz P, Czarnecka K, Królicki L, Mikiciuk-Olasik E, Szymański P. Radiolabeled peptides and antibodies in medicine. Bioconjug Chem 2021; 32(1): 25-42. doi: 10.1021/acs.bioconjchem.0c00617 PMID: 33325685
  102. Thompson S, Ballard B, Jiang Z, et al. 166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: Comparison with 188Re radiolabel. Nucl Med Biol 2014; 41(3): 276-81. doi: 10.1016/j.nucmedbio.2013.12.015 PMID: 24533987
  103. Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J Clin Invest 2007; 117(8): 2067-74. doi: 10.1172/JCI31988 PMID: 17671641
  104. Hojjat-Farsangi M. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Int J Mol Sci 2014; 15(8): 13768-801. doi: 10.3390/ijms150813768 PMID: 25110867
  105. Steeghs N, Nortier JWR, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 2007; 14(2): 942-53. doi: 10.1245/s10434-006-9227-1 PMID: 17103252
  106. Tong CWS, Wu M, Cho WCS, To KKW. Recent advances in the treatment of breast cancer. Front Oncol 2018; 8: 227. doi: 10.3389/fonc.2018.00227 PMID: 29963498
  107. Jazieh K, Bell R, Agarwal N, Abraham J. Novel targeted therapies for metastatic breast cancer. Ann Transl Med 2020; 8(14): 907. doi: 10.21037/atm.2020.03.43 PMID: 32793751
  108. Gajria D, Chandarlapaty S. HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 2011; 11(2): 263-75. doi: 10.1586/era.10.226 PMID: 21342044
  109. Wang C, Chen J, Xu X, et al. Dual HER2 blockade in neoadjuvant treatment of HER2+ breast cancer: A meta-analysis and review. Technol Cancer Res Treat 2020; 19. doi: 10.1177/1533033820960721 PMID: 32990165
  110. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat Rev Immunol 2020; 20(11): 651-68. doi: 10.1038/s41577-020-0306-5 PMID: 32433532
  111. Corraliza-Gorjón I, Somovilla-Crespo B, Santamaria S, Garcia-Sanz JA, Kremer L. New strategies using antibody combinations to increase cancer treatment effectiveness. Front Immunol 2017; 8: 1804. doi: 10.3389/fimmu.2017.01804 PMID: 29312320
  112. Jin S, Sun Y, Liang X, et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther 2022; 7(1): 39. doi: 10.1038/s41392-021-00868-x PMID: 35132063
  113. Kuroda T, Kumagi T, Yokota T, et al. Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: A multicenter review of 895 patients. BMC Gastroenterol 2017; 17(1): 66. doi: 10.1186/s12876-017-0623-8 PMID: 28532457
  114. Ko JJ, Kennecke HF, Lim HJ, et al. Reasons for underuse of adjuvant chemotherapy in elderly patients with stage III colon cancer. Clin Colorectal Cancer 2016; 15(2): 179-85. doi: 10.1016/j.clcc.2015.09.002 PMID: 26520019
  115. Holub K, Biete A. Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients. Clin Transl Oncol 2019; 21(7): 836-44. doi: 10.1007/s12094-018-1991-4 PMID: 30470994
  116. Shrivastava S, Mahantshetty U, Engineer R, et al. Cisplatin chemoradiotherapy vs radiotherapy in FIGO stage IIIB squamous cell carcinoma of the uterine cervix. JAMA Oncol 2018; 4(4): 506-13. doi: 10.1001/jamaoncol.2017.5179 PMID: 29423520
  117. Moore KN, Java JJ, Slaughter KN, et al. Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecol Oncol 2016; 143(2): 294-301. doi: 10.1016/j.ygyno.2016.08.317 PMID: 27542967
  118. Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: The Cancer and Leukemia Group B Experience. J Clin Oncol 2007; 25(24): 3699-704. doi: 10.1200/JCO.2007.10.9710 PMID: 17704418
  119. Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 2000; 57(1): 95-7. doi: 10.1001/archpsyc.57.1.95 PMID: 10632242
  120. Nyrop KA, Deal AM, Chen YT, et al. Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer. Cancer 2021; 127(6): 957-67. doi: 10.1002/cncr.33329 PMID: 33216355
  121. Manjelievskaia J, Brown D, McGlynn KA, Anderson W, Shriver CD, Zhu K. Chemotherapy use and survival among young and middle-aged patients with colon cancer. JAMA Surg 2017; 152(5): 452-9. doi: 10.1001/jamasurg.2016.5050 PMID: 28122072
  122. Yoon TI, Hwang UK, Kim ET, et al. Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy. Breast Cancer Res Treat 2017; 165(2): 311-20. doi: 10.1007/s10549-017-4331-4 PMID: 28601930
  123. McKevitt E, Cheifetz R, DeVries K, et al. Sentinel node biopsy should not be routine in older patients with ER-positive HER2-negative breast cancer who are willing and able to take hormone therapy. Ann Surg Oncol 2021; 28(11): 5950-7. doi: 10.1245/s10434-021-09839-6 PMID: 33817760
  124. Pepping RMC, Portielje JEA, van de Water W, de Glas NA. Primary endocrine therapy in older women with breast cancer. Curr Geriatr Rep 2017; 6(4): 239-46. doi: 10.1007/s13670-017-0223-z PMID: 29238654
  125. Rhee SG, Kang SW, Netto LE, Seo MS, Stadtman ER. A family of novel peroxidases, peroxiredoxins. Biofactors 1999; 10(2-3): 207-9. doi: 10.1002/biof.5520100218 PMID: 10609884
  126. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017; 377(4): 338-51. doi: 10.1056/NEJMoa1702900 PMID: 28578639
  127. Ferrigni E, Bergom C, Yin Z, Szabo A, Kong AL. Breast cancer in women aged 80 years or older: An analysis of treatment patterns and disease outcomes. Clin Breast Cancer 2019; 19(3): 157-64. doi: 10.1016/j.clbc.2019.01.007 PMID: 30819504
  128. Freedman RA, Tolaney SM. Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: A review. Breast Cancer Res Treat 2018; 167(3): 607-14. doi: 10.1007/s10549-017-4560-6 PMID: 29103175
  129. Derks MGM, Bastiaannet E, Kiderlen M, et al. Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: A population-based cohort study from the EURECCA Breast Cancer Group. Br J Cancer 2018; 119(1): 121-9. doi: 10.1038/s41416-018-0090-1 PMID: 29875471
  130. Xia Q, Dong S, Bian PD, Wang J, Li CJ. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma. Eur Arch Otorhinolaryngol 2016; 273(4): 1037-43. doi: 10.1007/s00405-015-3564-2 PMID: 25744048
  131. Lee S, Seo JH. Current strategies of endocrine therapy in elderly patients with breast cancer. BioMed Res Int 2018; 2018: 1-12. doi: 10.1155/2018/6074808 PMID: 29581979
  132. Serra F, Lapidari P, Quaquarini E, Tagliaferri B, Sottotetti F, Palumbo R. Palbociclib in metastatic breast cancer: Current evidence and real-life data. Drugs Context 2019; 8: 1-16. doi: 10.7573/dic.212579 PMID: 31391852
  133. Rugo HS, Turner NC, Finn RS, et al. Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: A pooled analysis of randomised PALOMA clinical studies. Eur J Cancer 2018; 101: 123-33. doi: 10.1016/j.ejca.2018.05.017 PMID: 30053671
  134. Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations. Front Oncol 2018; 8: 86. doi: 10.3389/fonc.2018.00086 PMID: 29644214
  135. Pawelec G. Immunosenescence and cancer. Biogerontology 2017; 18(4): 717-21. doi: 10.1007/s10522-017-9682-z PMID: 28220304
  136. Betof AS, Nipp RD, Giobbie-Hurder A, et al. Impact of age on outcomes with immunotherapy for patients with melanoma. Oncologist 2017; 22(8): 963-71. doi: 10.1634/theoncologist.2016-0450 PMID: 28476944
  137. Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016; 315(15): 1600-9. doi: 10.1001/jama.2016.4059 PMID: 27092830
  138. Johns AC, Wei L, Grogan M, et al. Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. J Geriatr Oncol 2021; 12(5): 813-9. doi: 10.1016/j.jgo.2021.02.002 PMID: 33627226
  139. Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 2019; 30(4): 582-8. doi: 10.1093/annonc/mdz011 PMID: 30715153
  140. Galli G, De Toma A, Pagani F, et al. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer 2019; 137: 38-42. doi: 10.1016/j.lungcan.2019.08.030 PMID: 31526910
  141. Luciani A, Marra A, Toschi L, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients aged ≥ 75 years with non–small-cell lung cancer (NSCLC): An italian, multicenter, retrospective study. Clin Lung Cancer 2020; 21(6): e567-71. doi: 10.1016/j.cllc.2020.05.004 PMID: 32591311
  142. Corbaux P, Maillet D, Boespflug A, et al. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting. Eur J Cancer 2019; 121: 192-201. doi: 10.1016/j.ejca.2019.08.027 PMID: 31590080
  143. Muroya T, Suehiro Y, Umayahara K, et al. Photodynamic therapy (PDT) for early cervical cancer. Gan To Kagaku Ryoho 1996; 23(1): 47-56. PMID: 8546469
  144. Rkein AM, Ozog DM. Photodynamic therapy. Dermatol Clin 2014; 32(3): 415-25. doi: 10.1016/j.det.2014.03.009
  145. Roozeboom MH, Arits AHMM, Mosterd K, et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: A single-blind, noninferiority, randomized controlled trial. J Invest Dermatol 2016; 136(8): 1568-74. doi: 10.1016/j.jid.2016.03.043 PMID: 27113429
  146. Jansen MHE, Mosterd K, Arits AHMM, et al. Five-Year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. J Invest Dermatol 2018; 138(3): 527-33. doi: 10.1016/j.jid.2017.09.033 PMID: 29045820
  147. Hamblin MR. Photodynamic therapy for cancer: What’s past is prologue. Photochem Photobiol 2020; 96(3): 506-16. doi: 10.1111/php.13190 PMID: 31820824
  148. Gunaydin G, Gedik ME, Ayan S. Photodynamic therapy—current limitations and novel approaches. Front Chem 2021; 9: 691697. doi: 10.3389/fchem.2021.691697 PMID: 34178948
  149. Frochot C, Mordon S. Update of the situation of clinical photodynamic therapy in Europe in the 2003–2018 period. JPP 2019; 23(04n05): 347-57. doi: 10.1142/S1088424619300027
  150. Park YK, Park CH. Clinical efficacy of photodynamic therapy. Obstet Gynecol Sci 2016; 59(6): 479-88. doi: 10.5468/ogs.2016.59.6.479 PMID: 27896250
  151. Huang S, Zheng S, Gong T, et al. Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older. Oncotarget 2017; 8(67): 112094-102. doi: 10.18632/oncotarget.22884 PMID: 29340114
  152. Jingu K, Takahashi N, Murakami Y, et al. Is concurrent chemotherapy with radiotherapy for esophageal cancer beneficial in patients aged 80 years or older? Anticancer Res 2019; 39(8): 4279-83. doi: 10.21873/anticanres.13592 PMID: 31366518
  153. Ciabatti S, Cammelli S, Frakulli R, et al. Radiotherapy of pancreatic cancer in older patients: A systematic review. J Geriatr Oncol 2019; 10(4): 534-9. doi: 10.1016/j.jgo.2018.09.007 PMID: 30270196
  154. Lancellotta V, Kovács G, Tagliaferri L, et al. Age is not a limiting factor in interventional radiotherapy (Brachytherapy) for patients with localized cancer. BioMed Res Int 2018; 2018: 1-10. doi: 10.1155/2018/2178469 PMID: 29581964
  155. Korpics MC, Block AM, Martin B, et al. Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy. Cancer 2017; 123(18): 3524-31. doi: 10.1002/cncr.30719 PMID: 28581675
  156. Jin YN, Zhang WJ, Cai XY, et al. The characteristics and survival outcomes in patients aged 70 years and older with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. Cancer Res Treat 2019; 51(1): 34-42. doi: 10.4143/crt.2017.551 PMID: 29409313
  157. Rotta JM, Rodrigues DB, Diniz JM, et al. Analysis of survival in patients with brain metastases treated surgically: Impact of age, gender, oncologic status, chemotherapy, radiotherapy, number and localization of lesions, and primary cancer site. Rev Assoc Med Bras 2018; 717-22.
  158. Takakusagi Y, Kano K, Shima S, et al. Clinical outcomes of radiotherapy in elderly and younger patients with t4 esophageal cancer: A retrospective single-center analysis. Anticancer Res 2022; 42(4): 2095-104. doi: 10.21873/anticanres.15691 PMID: 35347033
  159. Yang J, Cai H, Xiao ZX, Wang H, Yang P. Effect of radiotherapy on the survival of cervical cancer patients. Medicine 2019; 98(30): e16421. doi: 10.1097/MD.0000000000016421 PMID: 31348242
  160. Winawer SJ, Stewart ET, Zauber AG, et al. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. N Engl J Med 2000; 342(24): 1766-72. doi: 10.1056/NEJM200006153422401 PMID: 10852998
  161. Rashidi A, Ebadi M, Colditz GA, DiPersio JF. Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. Biol Blood Marrow Transplant 2016; 22(4): 651-7. doi: 10.1016/j.bbmt.2015.10.019 PMID: 26529178
  162. Garderet L, Beohou E, Caillot D, et al. Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: A prospective multicenter study. Haematologica 2016; 101(11): 1390-7. doi: 10.3324/haematol.2016.150334 PMID: 27612987
  163. Vaxman I, Visram A, Kumar S, et al. Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. Bone Marrow Transplant 2021; 56(5): 1144-50. doi: 10.1038/s41409-020-01159-9 PMID: 33273658
  164. Gudiol C, Albasanz-Puig A, Cuervo G, Carratalà J. Understanding and managing sepsis in patients with cancer in the era of antimicrobial resistance. Front Med 2021; 8: 636547. doi: 10.3389/fmed.2021.636547 PMID: 33869250
  165. Sanchez L, Sylvester M, Parrondo R, Mariotti V, Eloy JA, Chang VT. In-hospital mortality and post-transplantation complications in elderly multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: A population-based study. Biol Blood Marrow Transplant 2017; 23(7): 1203-7. doi: 10.1016/j.bbmt.2017.03.012 PMID: 28286198
  166. Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): A randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet 2016; 388(10044): 565-75. doi: 10.1016/S0140-6736(16)00739-X PMID: 27313086
  167. Master S, Koshy N, Mansour R, Shi R. Effect of stem cell transplant on survival in adult patients with acute lymphoblastic leukemia: NCDB analysis. Anticancer Res 2019; 39(4): 1899-906. doi: 10.21873/anticanres.13298 PMID: 30952731
  168. Barker JN, Wagner JE. Umbilical-cord blood transplantation for the treatment of cancer. Nat Rev Cancer 2003; 3(7): 526-32. doi: 10.1038/nrc1125 PMID: 12835672
  169. Veluchamy J, Spanholtz J, Kok N, et al. Umbilical cord blood stem cell derived NK cells as universal treatment for metastatic colorectal cancer using EGFR independent killing mechanisms. J Clin Oncol 2016; 34(S15): e14525-5. doi: 10.1200/JCO.2016.34.15_suppl.e14525
  170. Zhu Y, Ge J, Huang C, Liu H, Jiang H. Application of mesenchymal stem cell therapy for aging frailty: from mechanisms to therapeutics. Theranostics 2021; 11(12): 5675-85. doi: 10.7150/thno.46436 PMID: 33897874
  171. Schulman IH, Balkan W, Hare JM. Mesenchymal stem cell therapy for aging frailty. Front Nutr 2018; 5: 108. doi: 10.3389/fnut.2018.00108 PMID: 30498696
  172. Chen C, Kong ANT. Dietary cancer-chemopreventive compounds: From signaling and gene expression to pharmacological effects. Trends Pharmacol Sci 2005; 26(6): 318-26. doi: 10.1016/j.tips.2005.04.004 PMID: 15925707
  173. George BP, Chandran R, Abrahamse H. Role of phytochemicals in cancer chemoprevention: Insights. Antioxidants 2021; 10(9): 1455. doi: 10.3390/antiox10091455 PMID: 34573087
  174. Rather RA, Bhagat M. Cancer chemoprevention and piperine: Molecular mechanisms and therapeutic opportunities. Front Cell Dev Biol 2018; 6: 10. doi: 10.3389/fcell.2018.00010 PMID: 29497610
  175. Vafadar A, Shabaninejad Z, Movahedpour A, et al. Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells. Cell Biosci 2020; 10(1): 32. doi: 10.1186/s13578-020-00397-0 PMID: 32175075
  176. Ezzati M, Yousefi B, Velaei K, Safa A. A review on anti-cancer properties of Quercetin in breast cancer. Life Sci 2020; 248: 117463. doi: 10.1016/j.lfs.2020.117463 PMID: 32097663
  177. Vijayababu MR, Arunkumar A, Kanagaraj P, Arunakaran J. Effects of quercetin on insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and induction of apoptosis in human prostate cancer cells. J Carcinog 2006; 5(1): 10. doi: 10.1186/1477-3163-5-10 PMID: 16600019
  178. Tezerji S, Nazari Robati F, Abdolazimi H, Fallah A, Talaei B. Quercetin’s effects on colon cancer cells apoptosis and proliferation in a rat model of disease. Clin Nutr ESPEN 2022; 48: 441-5. doi: 10.1016/j.clnesp.2022.01.004 PMID: 35331526
  179. Asgharian P, Tazekand AP, Hosseini K, et al. Potential mechanisms of quercetin in cancer prevention: Focus on cellular and molecular targets. Cancer Cell Int 2022; 22(1): 257. doi: 10.1186/s12935-022-02677-w PMID: 35971151
  180. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res 2009; 2(5): 409-18. doi: 10.1158/1940-6207.CAPR-08-0160 PMID: 19401532
  181. Akter R, Rahman MH, Kaushik D, et al. Chemo-preventive action of resveratrol: Suppression of p53—a molecular targeting approach. Molecules 2021; 26(17): 5325. doi: 10.3390/molecules26175325 PMID: 34500758
  182. Yang ZJ, Huang SY, Zhou DD, et al. Effects and mechanisms of curcumin for the prevention and management of cancers: An updated review. Antioxidants 2022; 11(8): 1481. doi: 10.3390/antiox11081481 PMID: 36009200
  183. Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: Molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm 2010; 343(9): 489-99. doi: 10.1002/ardp.200900319 PMID: 20726007
  184. Wang H, Zhang K, Liu J, et al. Curcumin regulates cancer progression: Focus on ncRNAs and Molecular Signaling Pathways. Front Oncol 2021; 11: 660712. doi: 10.3389/fonc.2021.660712 PMID: 33912467
  185. Kumar NB, Besterman-Dahan K, Kang L, et al. Results of a randomized clinical trial of the action of several doses of lycopene in localized prostate cancer: Administration prior to radical prostatectomy. Clin Med Urol 2008; 1: CMU.S718. doi: 10.4137/CMU.S718 PMID: 20354574
  186. Holzapfel N, Holzapfel B, Champ S, Feldthusen J, Clements J, Hutmacher D. The potential role of lycopene for the prevention and therapy of prostate cancer: from molecular mechanisms to clinical evidence. Int J Mol Sci 2013; 14(7): 14620-46. doi: 10.3390/ijms140714620 PMID: 23857058
  187. Pavese JM, Farmer RL, Bergan RC. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev 2010; 29(3): 465-82. doi: 10.1007/s10555-010-9238-z PMID: 20730632
  188. Singh RP, Dhanalakshmi S, Agarwal R. Phytochemicals as cell cycle modulators--a less toxic approach in halting human cancers. Cell Cycle 2002; 1(3): 155-60. doi: 10.4161/cc.1.3.117 PMID: 12429925
  189. Kaur S, Kumar M, Kaur S. Role of phytochemicals in MAPK signaling pathway-mediated apoptosis: A possible strategy in cancer chemoprevention. In: Atta ur Rehman , Ed. Studies in Natural Products Chemistry. Elsevier 2016.
  190. Gaikwad S, Srivastava SK. Role of phytochemicals in perturbation of redox homeostasis in cancer. Antioxidants 2021; 10(1): 83. doi: 10.3390/antiox10010083 PMID: 33435480
  191. Béliveau R, Gingras D. Role of nutrition in preventing cancer. Can Fam Physician 2007; 53(11): 1905-11. PMID: 18000267
  192. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010; 15(6): 556-65. doi: 10.1634/theoncologist.2009-0285 PMID: 20507889
  193. Hamer J, Warner E. Lifestyle modifications for patients with breast cancer to improve prognosis and optimize overall health. CMAJ 2017; 189(7): E268-74. doi: 10.1503/cmaj.160464 PMID: 28246240
  194. Choi JW, Hua TNM. Impact of lifestyle behaviors on cancer risk and prevention. J Lifestyle Med 2021; 11(1): 1-7. doi: 10.15280/jlm.2021.11.1.1 PMID: 33763336
  195. Jia T, Liu Y, Fan Y, Wang L, Jiang E. Association of healthy diet and physical activity with breast cancer: Lifestyle interventions and oncology education. Front Public Health 2022; 10: 797794. doi: 10.3389/fpubh.2022.797794 PMID: 35400043
  196. Krishnan AV, Trump DL, Johnson CS, Feldman D. The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin North Am 2010; 39(2): 401-18. doi: 10.1016/j.ecl.2010.02.011
  197. Liu J, Ma D. The role of n-3 polyunsaturated fatty acids in the prevention and treatment of breast cancer. Nutrients 2014; 6(11): 5184-223. doi: 10.3390/nu6115184 PMID: 25412153
  198. Asefy Z, Tanomand A, Hoseinnejhad S, Ceferov Z, Oshaghi EA, Rashidi M. Unsaturated fatty acids as a co-therapeutic agents in cancer treatment. Mol Biol Rep 2021; 48(3): 2909-16. doi: 10.1007/s11033-021-06319-8 PMID: 33821440
  199. Bosetti C, Franceschi S, Levi F, Negri E, Talamini R, Vecchia CL. Smoking and drinking cessation and the risk of oesophageal cancer. Br J Cancer 2000; 83(5): 689-91. doi: 10.1054/bjoc.2000.1274 PMID: 10944613
  200. Marron M, Boffetta P, Zhang ZF, et al. Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk. Int J Epidemiol 2010; 39(1): 182-96. doi: 10.1093/ije/dyp291 PMID: 19805488
  201. Yeo Y, Han K, Shin DW, et al. Changes in smoking, alcohol consumption, and the risk of thyroid cancer: A population-based korean cohort study. Cancers 2021; 13(10): 2343. doi: 10.3390/cancers13102343 PMID: 34066228
  202. Gulia KK, Kumar VM. Sleep disorders in the elderly: A growing challenge. Psychogeriatrics 2018; 18(3): 155-65. doi: 10.1111/psyg.12319 PMID: 29878472
  203. Townsend-Roccichelli J, Sanford JT, VandeWaa E. Managing sleep disorders in the elderly. Nurse Pract 2010; 35(5): 30-7. doi: 10.1097/01.NPR.0000371296.98371.7e PMID: 20395765
  204. Chandler PD, Chen WY, Ajala ON, et al. Effect of vitamin D 3 supplements on development of advanced cancer. JAMA Netw Open 2020; 3(11): e2025850. doi: 10.1001/jamanetworkopen.2020.25850 PMID: 33206192
  205. Li Y, Lin Q, Lu X, Li W. Post-diagnosis use of antioxidant vitamin supplements and breast cancer prognosis: A systematic review and meta-analysis. Clin Breast Cancer 2021; 21(6): 477-85. doi: 10.1016/j.clbc.2021.09.001 PMID: 34635464
  206. Zhang SL, Chen TS, Ma CY, et al. Effect of vitamin B supplementation on cancer incidence, death due to cancer, and total mortality. Medicine 2016; 95(31): e3485. doi: 10.1097/MD.0000000000003485 PMID: 27495015
  207. Dai S, Mo Y, Wang Y, et al. Chronic stress promotes cancer development. Front Oncol 2020; 10: 1492. doi: 10.3389/fonc.2020.01492 PMID: 32974180
  208. Eckerling A, Ricon-Becker I, Sorski L, Sandbank E, Ben-Eliyahu S. Stress and cancer: Mechanisms, significance and future directions. Nat Rev Cancer 2021; 21(12): 767-85. doi: 10.1038/s41568-021-00395-5 PMID: 34508247
  209. Moreno-Smith M, Lutgendorf SK, Sood AK. Impact of stress on cancer metastasis. Future Oncol 2010; 6(12): 1863-81. doi: 10.2217/fon.10.142 PMID: 21142861
  210. Khodabakhshi Koolaee A, Falsafinejad MR, Akbari ME. The effect of stress management model in quality of life in breast cancer women. Iran J Cancer Prev 2015; 8(4): e3435. doi: 10.17795/ijcp-3435 PMID: 26478793
  211. Oh HM, Son CG. The risk of psychological stress on cancer recurrence: A systematic review. Cancers 2021; 13(22): 5816. doi: 10.3390/cancers13225816 PMID: 34830968
  212. Hulbert-Williams NJ, Beatty L, Dhillon HM. Psychological support for patients with cancer: Evidence review and suggestions for future directions. Curr Opin Support Palliat Care 2018; 12(3): 276-92. doi: 10.1097/SPC.0000000000000360 PMID: 30074924
  213. Agarwal R, Epstein A. The role of palliative care in oncology. Semin Intervent Radiol 2017; 34(4): 307-12. doi: 10.1055/s-0037-1608702 PMID: 29249853
  214. Cao Z, Xu C, Yang H, Li S, Wang Y. The role of healthy lifestyle in cancer incidence and temporal transitions to cardiometabolic disease. JACC: CardioOncology 2021; 3(5): 663-74. doi: 10.1016/j.jaccao.2021.09.016 PMID: 34988474
  215. Li Y, Schoufour J, Wang DD, et al. Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: Prospective cohort study. BMJ 2020; 368: l6669. doi: 10.1136/bmj.l6669 PMID: 31915124

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers